{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T07:12:14Z","timestamp":1777101134169,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reproductive Toxicology"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.reprotox.2014.02.004","type":"journal-article","created":{"date-parts":[[2014,3,3]],"date-time":"2014-03-03T17:17:37Z","timestamp":1393867057000},"page":"40-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["The fetal safety of Levetiracetam: A systematic review"],"prefix":"10.1016","volume":"46","author":[{"given":"Shahnaz Akhtar","family":"Chaudhry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geert\u2019t","family":"Jong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gideon","family":"Koren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.reprotox.2014.02.004_bib0005","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.seizure.2012.01.005","article-title":"Valproate and the risk for congenital malformations: is formulation and dosage regime important?","volume":"21","author":"Mawhinney","year":"2012","journal-title":"Seizure J. Br. Epilepsy Assoc."},{"key":"10.1016\/j.reprotox.2014.02.004_bib0010","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1136\/jnnp.2003.029132","article-title":"The longer term outcome of children born to mothers with epilepsy","volume":"75","author":"Adab","year":"2004","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.reprotox.2014.02.004_bib0015","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1212\/01.wnl.0000319693.10338.b9","article-title":"Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM study","volume":"71","author":"Faught","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.reprotox.2014.02.004_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2011.11.025","article-title":"Prescription drug use in pregnancy: a retrospective, population-based study in British Columbia, Canada (2001\u20132006)","volume":"34","author":"Daw","year":"2012","journal-title":"Clin. Ther."},{"key":"10.1016\/j.reprotox.2014.02.004_bib0025","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2147\/NDT.S1655","article-title":"Monotherapy for partial epilepsy: focus on levetiracetam","volume":"4","author":"Gambardella","year":"2008","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.reprotox.2014.02.004_bib0030","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1586\/ern.12.32","article-title":"Second-generation antiepileptic drugs and pregnancy: a guide for clinicians","volume":"12","author":"Reimers","year":"2012","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.reprotox.2014.02.004_bib0035","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2165\/00003495-200060040-00004","article-title":"Levetiracetam. A review of its adjunctive use in the management of partial onset seizures","volume":"60","author":"Dooley","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.reprotox.2014.02.004_bib0040","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1592\/phco.21.17.1375.34432","article-title":"Levetiracetam: a novel antiepileptic drug","volume":"21","author":"Hovinga","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.reprotox.2014.02.004_bib0045","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.seizure.2007.11.015","article-title":"Seizure control and pharmacokinetics of antiepileptic drugs in pregnant women with epilepsy","volume":"17","author":"Brodtkorb","year":"2008","journal-title":"Seizure J. Br. Epilepsy Assoc."},{"key":"10.1016\/j.reprotox.2014.02.004_bib0050","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2165\/00003088-200645110-00002","article-title":"Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?","volume":"45","author":"Johannessen","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.reprotox.2014.02.004_bib0055","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2165\/00003088-200443110-00002","article-title":"Clinical pharmacokinetics of levetiracetam","volume":"43","author":"Patsalos","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.reprotox.2014.02.004_bib0060","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1528-1167.2007.01032.x","article-title":"Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation","volume":"48","author":"Tomson","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.reprotox.2014.02.004_bib0065","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.seizure.2007.11.027","article-title":"Serum concentration\/dose ratio of levetiracetam before, during and after pregnancy","volume":"17","author":"Westin","year":"2008","journal-title":"Seizure J. Br. Epilepsy Assoc."},{"key":"10.1016\/j.reprotox.2014.02.004_bib0070","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1345\/aph.1M231","article-title":"Levetiracetam use in pregnancy","volume":"43","author":"Longo","year":"2009","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.reprotox.2014.02.004_bib0075","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.reprotox.2004.12.001","article-title":"Levetiracetam use and pregnancy outcome","volume":"20","author":"Ten Berg","year":"2005","journal-title":"Reprod. Toxicol. Elmsford N Y"},{"key":"10.1016\/j.reprotox.2014.02.004_bib0080","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1046\/j.1528-1157.2003.21503.x","article-title":"Developmental outcome of levetiracetam, its major metabolite in humans, 2-pyrrolidinone N-butyric acid, and its enantiomer (R)-alpha-ethyl-oxo-pyrrolidine acetamide in a mouse model of teratogenicity","volume":"44","author":"Isoherranen","year":"2003","journal-title":"Epilepsia"},{"key":"10.1016\/j.reprotox.2014.02.004_bib0085","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/j.1528-1167.2010.02525.x","article-title":"Pregnancy registries: differences, similarities, and possible harmonization","volume":"51","author":"Tomson","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.reprotox.2014.02.004_bib0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1096-9926(199901)59:1<1::AID-TERA1>3.0.CO;2-L","article-title":"Need for inclusion and exclusion criteria for the structural abnormalities recorded in children born from exposed pregnancies","volume":"59","author":"Holmes","year":"1999","journal-title":"Teratology"},{"key":"10.1016\/j.reprotox.2014.02.004_bib0095","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1212\/WNL.0b013e3182574f39","article-title":"Comparative safety of antiepileptic drugs during pregnancy","volume":"78","author":"Hern\u00e1ndez-D\u00edaz","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.reprotox.2014.02.004_bib0100","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0b013e31827f0874","article-title":"Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers","author":"Mawhinney","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.reprotox.2014.02.004_bib0105","first-page":"57","article-title":"Teratogenicity of the newer antiepileptic drugs \u2013 the Australian experience","volume":"19","author":"Vajda","year":"2012","journal-title":"J. Clin. Neurosci. Off. J. Neurosurg. Soc. Aust."},{"key":"10.1016\/j.reprotox.2014.02.004_bib0110","series-title":"UCB Antiepileptic Drug Pregnancy Registry \u2013 Keppra\u00ae data in (257AD). Direct link to abstract is http:\/\/www.aesnet.org\/go\/publications\/aes-abstracts\/abstract-search?mode=display&sy=2010&sb=all&startrow=961&id=12457","author":"Montouris","year":"2012"},{"key":"10.1016\/j.reprotox.2014.02.004_bib0115","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1001\/jama.2011.624","article-title":"Newer-generation antiepileptic drugs and the risk of major birth defects","volume":"305","author":"M\u00f8lgaard-Nielsen","year":"2011","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.reprotox.2014.02.004_bib0120","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1474-4422(11)70107-7","article-title":"Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry","volume":"10","author":"Tomson","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.reprotox.2014.02.004_bib0125","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1212\/01.wnl.0000244491.48937.55","article-title":"Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register","volume":"67","author":"Hunt","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.reprotox.2014.02.004_bib0130","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1212\/WNL.0b013e3182088297","article-title":"Child development following in utero exposure: levetiracetam vs sodium valproate","volume":"76","author":"Shallcross","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.reprotox.2014.02.004_bib0135","series-title":"A first look at the language and developmental abilities of children aged three to four years exposed in utero to Levetiracetam","author":"Shallcross","year":"2010"},{"key":"10.1016\/j.reprotox.2014.02.004_bib0140","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1586\/14737175.6.7.1077","article-title":"Use of antiepileptic drugs in pregnancy","volume":"6","author":"Tatum","year":"2006","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.reprotox.2014.02.004_bib0145","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1212\/WNL.61.6_suppl_2.S35","article-title":"Antiepileptic drug pharmacokinetics during pregnancy and lactation","volume":"61","author":"Pennell","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.reprotox.2014.02.004_bib0150","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1212\/01.WNL.0000154514.82948.69","article-title":"Neuropsychological effects of exposure to anticonvulsant medication in utero","volume":"64","author":"Vinten","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.reprotox.2014.02.004_bib0155","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.eplepsyres.2011.04.001","article-title":"No effect of oral contraceptives on the metabolism of levetiracetam","volume":"95","author":"Sabers","year":"2011","journal-title":"Epilepsy Res."}],"container-title":["Reproductive Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890623814000380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890623814000380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:36:21Z","timestamp":1760189781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890623814000380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":31,"alternative-id":["S0890623814000380"],"URL":"https:\/\/doi.org\/10.1016\/j.reprotox.2014.02.004","relation":{},"ISSN":["0890-6238"],"issn-type":[{"value":"0890-6238","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The fetal safety of Levetiracetam: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Reproductive Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reprotox.2014.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}